ArticleBiomedicines2026
From Biomarker Discovery to Targeted Clinical Application: Addressing Translational Gaps in Early Cancer Detection.
Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite extensive progress in breast cancer biomarker research, only a limited proportion of candidate biomarkers successfully transition from early discovery to clinically validated tools for targeted early detection. This article examines the key translational barriers that impede this progression across the biomarker development continuum. Five major gaps are identified: (i) discovery-to-clinical relevance, (ii) methodological and analytical validation, (iii) regulatory and administrative complexity, (iv) translational performance and real-world integration, and (v) equity and deployment challenges. Collectively, these gaps highlight limitations not only in scientific and methodological rigor but also in validation frameworks, regulatory alignment, implementation feasibility, and healthcare system equity. This article emphasizes that successful biomarker translation requires more than analytical validity. Finally, it requires a supportive ecosystem that enables effective breast cancer early detection strategies and improves population-level outcomes in breast cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.